Esophageal Cancer Clinical Trial
Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach
Summary
The purpose of this study is to determine whether molecular profile-directed therapy (otherwise known as personalized treatment) can improve the effectiveness of standard chemotherapy combinations for patients with esophagogastric adenocarcinoma. A series of tests will be performed on a sample of tumor; based on the results of these tests, a patient will be assigned to a chemotherapy treatment.
Eligibility Criteria
Inclusion Criteria:
Advanced, measurable metastatic esophagogastric adenocarcinoma by RECIST criteria
Patients who have had surgery or radiotherapy with or without neoadjuvant or adjuvant chemotherapy (the wash-out period will be at least 1 month)
Patients who are not eligible for resection and are chemotherapy naïve
Patients with HER2(-) status
Patients who have tumor deposit(s) that are easily accessible by ultrasound or CT guidance
Patients must have adequate organ function
Patients must provide written informed consent
Exclusion Criteria:
Active concurrent malignancy, other than superficial, non-squamous cell carcinoma of the skin or uterine cervix, within the past three years
ECOG performance status worse than 2
Prior oral or intravenous chemotherapy for metastatic disease
Patients with comorbidities that prevent them from being able to receive the chemotherapy regimen
cardiac ejection fraction 45% or greater
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Washington District of Columbia, 20057, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.